GSK Tykerb Priced At Discount To Herceptin In Metastatic Breast Cancer
Executive Summary
GlaxoSmithKline is pricing its breast cancer therapy Tykerb at a slight discount to Genentech's Herceptin (trastuzumab) in the metastatic breast cancer setting
You may also be interested in...
From Playing It Safe To All-In: Genentech Takes Risks With Oncology Pipeline
Compared to its old oncology R&D lineup, Genentech's current cancer pipeline makes it clear that the company is embracing a new, riskier development strategy
From Playing It Safe To All-In: Genentech Takes Risks With Oncology Pipeline
Compared to its old oncology R&D lineup, Genentech's current cancer pipeline makes it clear that the company is embracing a new, riskier development strategy
What’s In An Abstract? A Preview Of ASCO Annual Meeting Highlights
Data supporting first-line use of Lilly's Alimta in non-small cell lung cancer and GlaxoSmithKline's data on combining two targeted oncologics - Tykerb and Herceptin - are among the highlights of the massive data drop from the upcoming American Society of Clinical Oncology annual meeting